Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Data of the largest meta-analyzes of beta-blockers use in arterial hypertension is presented. The role of beta-blockers among other basic groups of antihypertensive drugs (thiazide diuretics, calcium channel blockers, ACE inhibitors) is evaluated. Special considerations of beta-blockers use in hypertensive patients with diabetes mellitus and chronic heart failure are discussed. Special attention is paid to bisoprolol.

About the Author

M. V. Leonova
Russian National Research Medical University named after N.I. Pirogov
Russian Federation


1. Wright J.M., Musini V.M. First-line drugs for hypertension. Cohrane Database Syst Rev 2009;(3):

2. CD001841.

3. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.

4. Lindholm L.H., Carlberg B., Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553.

5. Bangalore S., Wild D., Parkar S. et al. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. JACC 2008;52:1062-1072.

6. Khan N., McAlister F .A. Re-examining the efficacy of b-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174(12):1737-1742.

7. Elliott W.J., Meyer P .M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta- analysis. Lancet 2007;369:201–207.

8. Holman R.R., Paul S.K., Bethel M.A. et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576.

9. Shorr R.I., Ray W.A., Daugherty J.R. Griffin M.R. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278(1):40-43.

10. Leonova M.V., Belousov Yu.B., Shteynberg L.L., Galitskiy A.A. Results farmakoepide-miologichesko- go study of hypertension PIFAGOR III (a survey of patients with hypertension). Sistemnye Gipertenzii 2010; (2): 33-39. Russian (Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Г алицкий А.А. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III (опрос пациентов с АГ). Системные Гипертензии 2010; 2: 33-39).

11. Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689.

12. Bühler F .R., Berglund G., Anderson O.K. et al. Double-blind comparison of the cardioselective beta- blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986;8 (Suppl 11):S122-127.

13. Czuriga I., Riecansky I., Bodnar J. et al. Cardioselective beta-blocker nebivolol with bisoprolol in hy- pertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular Drugs and Therapy 2003;17 (3): 257-263.

14. Hiltunen T.P ., Suonsyrjä T., Hannila-Handelberg T. et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007;20(3):311-318.

15. Frithz G. Influence on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001;4:229–230.

16. Haneda T., Ido A., Fujikane T., Tanaka H. et al. Effect of bisoprolol, a beta 1-selective beta-blocker , on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jap J Geriatrics 1998;35(1):33-38.

17. Vulpis V., Antonacci A., Prandi P . et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Minerva Med 1991;82(4):189- 193.

18. Wang B., Song W., Liu G. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus. Chin J Internal Med 2005;44:503-505.

19. Dominguez L.J., Barbagallo M., Jacober S.J. et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997;10(12 Pt 1):1349-1355.

20. Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8 (Sup- pl 11):S96-99.

21. Mychka V.B., Sergienko V.B., Gornostaev V.V. et al. Effect of treatment with bisoprolol on cerebral perfusion in patients with metabolic syndrome. Arterial'naya Gipertenziya 2003; 9(5): 160-163. Russian (Мычка В.Б., Сергиенко В.Б., Г орностаев В.В. и др. Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом. Артериальная Гипертензия 2003; 9(5): 160-163).

22. Smith C., Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999;13(2):123-126.

23. Superko H.R., Haskell W.L., Krauss R.M. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993;101(1):1-8.

24. Fogari R., Zoppi A., Pasotti C. et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. J Cardiovasc Pharmacol 1989;14(Suppl 7):S28-32.

25. Weiner L, Frithz G. Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S106-112.

26. Frithz G., Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cho- lesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S134-138.

For citation:

Leonova M.V. BETA-BLOCKERS IN THE TREATMENT OF ARTERIAL HYPERTENSION: EVIDENCE BASED DATA AND REAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2012;8(1):75-80. (In Russ.)

Views: 588

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)